New radiation therapy shows promise for slowing prostate cancer spread

NCT ID NCT04443062

Completed Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested a drug called Lutetium-177-PSMA-617, which delivers radiation directly to prostate cancer cells. It included 58 men with prostate cancer that had spread to a few spots in bones or lymph nodes but was still hormone-sensitive. The study compared the drug to standard care to see if it could delay disease progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lutetium-177-PSMA-617 (a targeted radioactive drug)
What this could lead to: If successful, this could offer a new treatment option for men with prostate cancer that has spread to a few places, potentially delaying the need for stronger hormone therapy.
What could go wrong: This is a small, early-phase study with only 58 participants. The treatment may not work better than standard care, and there are risks from radiation exposure to healthy tissues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HORMONE-SENSITIVE OLIGO-METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Amsterdam UMC

Amsterdam, Netherlands
German Oncology Center

Limassol, Cyprus
Radboud University

Nijmegen, Netherlands
University Medical Center Groningen

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.